[Antineovascular gene therapy by Ago2 knockdown]

Area of Science:

• Molecular Biology
• Cell Biology
• Biotechnology

Background:

• Small interfering RNA (siRNA) mediates sequence-dependent gene silencing.
• Polycation liposomes (PCL) were previously developed for efficient plasmid DNA delivery.
• Optimizing PCL for siRNA delivery is crucial for gene silencing applications.

Purpose of the Study:

• To optimize polycation liposomes (PCL) for small interfering RNA (siRNA) transfection.
• To investigate the role of Argonaute2 (Ago2) in angiogenesis using siRNA.
• To develop a systemic siRNA delivery system targeting angiogenic vessels for potential tumor treatment.

Main Methods:

• siRNA targeting Argonaute2 (siAgo2) was delivered using optimized polycation liposomes (PCL).
• Human umbilical vein endothelial cells (HUVECs) were used as an in vitro angiogenesis model, stimulated with vascular endothelial growth factor (VEGF).
• siRNA delivery systems were further modified with polyethylene glycol (PEG) and functional peptides (e.g., APRPG) for enhanced cellular uptake.

Main Results:

• Ago2 knockdown using PCL-siAgo2 significantly suppressed endothelial cell proliferation and tube formation, key processes in angiogenesis.
• siAgo2 treatment increased apoptotic cells, as indicated by TUNEL staining, compared to control siRNA.
• Peptide-modified liposomes demonstrated enhanced cellular uptake of siRNA compared to non-modified liposomes.

Conclusions:

• Argonaute2 (Ago2) plays a critical role in regulating angiogenesis.
• siRNA delivery via optimized polycation liposomes, especially peptide-modified ones, shows promise for targeting angiogenesis.
• APRPG-modified liposomal siAgo2 may serve as a potential therapeutic strategy for tumor treatment by inhibiting angiogenesis.